The Hindu·4 min read·hard
What's the deal with peptides? The hyped market under U.S. review
A
AFP
✦AI Summary
The U.S. FDA is reviewing whether certain peptides, popular among wellness enthusiasts for anti-aging and performance, should be approved for compounding. Medical experts warn of a lack of clinical data, while proponents argue that current restrictions have created an unsafe gray market.
Glowing skin, deeper sleep, stronger muscles, an alert mind?
healthsciencepolitics
✦
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in